Delgocitinib, also known as UGT12734, is a Janus kinase (JAK) inhibitor investigated for its therapeutic potential [1]. The synthesis of delgocitinib is detailed in U.S. Patent Application Publication No. US20140187534A1 [1].
What is the chemical structure of delgocitinib?
Delgocitinib is chemically described as 3-((1-(cyclopropylsulfonyl)azetidin-3-yl)amino)-5-fluoro-2-(4-methoxyphenyl)isonicotinamide [1].
How is delgocitinib synthesized according to U.S. Patent Application Publication No. US20140187534A1?
The patent application outlines a synthetic route involving several steps. A key intermediate is 3-amino-5-fluoro-2-(4-methoxyphenyl)isonicotinamide. This intermediate is then reacted with a cyclopropylsulfonyl azetidine derivative to form delgocitinib [1]. Specific reagents and reaction conditions, such as solvents and catalysts, are detailed within the patent document to achieve the desired compound [1].
What are the potential therapeutic uses of delgocitinib?
Delgocitinib has been explored for the treatment of various conditions due to its ability to inhibit Janus kinases, which play a role in immune responses [2]. Research has investigated its efficacy in dermatological conditions such as atopic dermatitis [2, 3].
What is the patent status of delgocitinib?
Information on the patent landscape for delgocitinib, including its patent expiration dates and any granted patents, can be found through resources like DrugPatentWatch.com [4]. The patent application US20140187534A1 is one document in the public record concerning this compound [1].
Are there other JAK inhibitors similar to delgocitinib?
Yes, delgocitinib belongs to a class of drugs known as JAK inhibitors. Other JAK inhibitors, such as tofacitinib, baricitinib, and upadacitinib, are also approved or in development for various autoimmune and inflammatory conditions [5]. These inhibitors target different JAK family members or exhibit varying selectivity profiles.
What are the clinical trial findings for delgocitinib?
Clinical trials have assessed delgocitinib's safety and efficacy. For example, studies in patients with atopic dermatitis have evaluated its impact on skin severity and itch [2, 3]. Data from these trials contribute to understanding its therapeutic profile and potential side effects.
Sources:
1. https://patents.google.com/patent/US20140187534A1/
2. https://www.nejm.org/doi/full/10.1056/NEJMoa2024940
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878190/
4. https://drugpatentwatch.com/
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982228/